Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders
The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.
Bicoastal life science VC aims for $375 million third fund
It looks like Clarus Ventures is planning to reload with investment capital for life science companies. The Boston- and San Francisco-based venture firm revealed in a SEC filing it’s looking to raise up to $375 million for a third fund. Clarus invests mainly in biotech, with a few medtech and diagnostics companies in the mix. […]
presented by
Why Your Patients Are Leaving and How to Stop It
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
Cancer drugmaker TetraLogic Pharma raises $32M Series C
TetraLogic Pharmaceuticals has completed a $32 million Series C fund-raise that the company will use to push its cancer drug through a phase 2a study. The Malvern, Pennsylvania, company’s lead drug candidate, TL32711, is currently in a phase 1 study in patients with solid tumors, according to a statement from TetraLogic. The trial started in […]